Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH55 and GH21 in Advanced Solid Tumors with MAPK Pathway Aberrations
NCT07446725Phase 2Not yet recruiting
- Sponsor
- Genhouse Bio
- Start
- Feb 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH55, GH21 in solid tumor (advanced stage), sponsored by Genhouse Bio. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
GH55GH21
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07446725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446725.